Mo Jiancheng, Mai Le Ngoc Phuong, Priefer Ronny
Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA.
Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA.
Eur J Med Chem. 2021 Dec 5;225:113770. doi: 10.1016/j.ejmech.2021.113770. Epub 2021 Aug 11.
The identification of ruthenium(II) polypyridyl complexes as photosensitizers in photodynamic therapy (PDT) for the treatment of cancer is progressing rapidly. Due to their favorable photophysical and photochemical properties, Ru(II)-based photosensitizers have absorption in the visible spectrum, can be irradiated via one- and two-photon excitation within the PDT window, and yield potent oxygen-dependent and/or oxygen-independent photobiological activities. Herein, we present a current overview of the mechanisms of action and subcellular localization of Ru(II)-based photosensitizers in the treatment of cancer. These photosensitizers are highlighted from a medicinal chemistry and chemical biology perspective. However, although this field is burgeoning, challenges and limitations remain in the photosensitization strategies and clinical translation.
钌（II）多吡啶配合物作为光动力疗法（PDT）中用于癌症治疗的光敏剂的研究正在迅速发展。由于其良好的光物理和光化学性质，基于钌（II）的光敏剂在可见光谱范围内有吸收，可在PDT窗口内通过单光子和双光子激发进行照射，并产生强大的氧依赖性和/或氧非依赖性光生物学活性。在此，我们对基于钌（II）的光敏剂在癌症治疗中的作用机制和亚细胞定位进行了当前综述。从药物化学和化学生物学的角度对这些光敏剂进行了重点介绍。然而，尽管该领域正在蓬勃发展，但在光敏化策略和临床转化方面仍存在挑战和局限性。
